A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Trial ID or NCT#

NCT03821233

Status

not recruiting iconNOT RECRUITING

Purpose

This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.

Official Title

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Mark D Pegram
Medical oncologist, Breast specialist
Susy Yuan-Huey Hung Professor

Contact us to find out if this trial is right for you.

Contact

Kaitlin Zablotsky
650-725-2142

View on ClinicalTrials.gov